Volume 4, Issue 2 (4-2019)
CJHR 2019, 4(2): 33-37 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Tabari-Khomeiran R, Bayazidi Y, Nikfar S, Homaie Rad E, Varmaghani M, Kokabisaghi F. Inequity in Access of Statins in Iran: A Panel Study Using Provincial Data. CJHR 2019; 4 (2) :33-37
URL: http://cjhr.gums.ac.ir/article-1-121-en.html
URL: http://cjhr.gums.ac.ir/article-1-121-en.html
Rasoul Tabari-Khomeiran1 
, Yahya Bayazidi2 , Shekoufeh Nikfar2 , Enayatollah Homaie Rad * 3, Mahdi Varmaghani4 , Fatemeh Kokabisaghi5
, Yahya Bayazidi2 , Shekoufeh Nikfar2 , Enayatollah Homaie Rad * 3, Mahdi Varmaghani4 , Fatemeh Kokabisaghi5
1- Social Determinants of Health Research Center, Guilan University of Medical Sciences, Rasht, Iran
2- School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
3- Social Determinants of Health Research Center, Guilan University of Medical Sciences, Rasht, Iran , homaierad@gmail.com
4- Social Determinants of Health Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
5- Healthcare and Law Department, School of Health Policy and Management, Erasmus University, Rotterdam, Netherlands
2- School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
3- Social Determinants of Health Research Center, Guilan University of Medical Sciences, Rasht, Iran , homaierad@gmail.com
4- Social Determinants of Health Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
5- Healthcare and Law Department, School of Health Policy and Management, Erasmus University, Rotterdam, Netherlands
Abstract: (2038 Views)
Background: Statins are among useful drug to prevent hyperlipidemia and subsequent cardiovascular diseases. Having an equal access to these drugs are very important for health policy makers.
Methods: Provincial data of statin supply for Iran in 2013 were used in this study. Concentration index, GINI coefficient, concentration curve and Lorenz curve were calculated to show the level of inequality in access of statins. The percentage of population more than 65 years old was used as the need index. A panel data regression was used to estimate the contributing factors of inequality.
Results: GINI index was 0.297 for lovastatin, 0.322 for atorvastatin and 0.526 for simvastatin. GINI index for overall statin use was 0.303. Concentration index was not significant for atorvastatin and simvastatin while it was 0.160 for lovastatin. The coefficient of income was -1.75 for lovastatin, 1.04 for atorvastatin and -1.117 for simvastatin. The regression model showed that household income was independently contributed to decrease in Lovastatin (B = -1.752) and Simvastatin (B = -1.118) and increase in Atorvastatin (B = 1.04) access. Higher percentage of people with academic education, the number of physician, and price of drug were another significant predictors of statin access.
Conclusion: The inequality for access in Simvastatin was greater than other statins. Household income and price of drug were among important contributors of statin access. For increasing access to statins it is suggested to increase the coverage of health insurance.
Methods: Provincial data of statin supply for Iran in 2013 were used in this study. Concentration index, GINI coefficient, concentration curve and Lorenz curve were calculated to show the level of inequality in access of statins. The percentage of population more than 65 years old was used as the need index. A panel data regression was used to estimate the contributing factors of inequality.
Results: GINI index was 0.297 for lovastatin, 0.322 for atorvastatin and 0.526 for simvastatin. GINI index for overall statin use was 0.303. Concentration index was not significant for atorvastatin and simvastatin while it was 0.160 for lovastatin. The coefficient of income was -1.75 for lovastatin, 1.04 for atorvastatin and -1.117 for simvastatin. The regression model showed that household income was independently contributed to decrease in Lovastatin (B = -1.752) and Simvastatin (B = -1.118) and increase in Atorvastatin (B = 1.04) access. Higher percentage of people with academic education, the number of physician, and price of drug were another significant predictors of statin access.
Conclusion: The inequality for access in Simvastatin was greater than other statins. Household income and price of drug were among important contributors of statin access. For increasing access to statins it is suggested to increase the coverage of health insurance.
Article Type: Original Contributions |
Subject:
Health Management
Received: 2018/11/20 | Accepted: 2019/02/24 | Published: 2019/04/1
Received: 2018/11/20 | Accepted: 2019/02/24 | Published: 2019/04/1
References
1. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282(24):2340-2346. doi:10.1001/jama.282.24.2340. [DOI:10.1001/jama.282.24.2340]
2. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;(1):CD004816. doi: 10.1002/14651858.CD004816.pub5. [DOI:10.1002/14651858.CD004816.pub5]
3. Tsivgoulis G, Kadlecová P, Kobayashi A, Czlonkowska A, Brozman M, Švigelj V, et al. Safety of statin pretreatment in intravenous thrombolysis for acute ischemic stroke. Stroke. 2015;46(9):2681-2684. doi: 10.1161/STROKEAHA.115.010244. [DOI:10.1161/STROKEAHA.115.010244]
4. Norris P, Horsburgh S, Becket G, Keown S, Arroll B, Lovelock K, et al. Equity in statin use in New Zealand. J Prim Health Care. 2014;6(1):17-22. doi: 10.1071/hc14017. [DOI:10.1071/HC14017]
5. Odubanjo E, Bennett K, Feely J. Influence of socioeconomic status on the quality of prescribing in the elderly -- a population based study. Br J Clin Pharmacol. 2004; 58(5):496-502. doi: 10.1111/j.1365-2125.2004.02179.x. [DOI:10.1111/j.1365-2125.2004.02179.x]
6. Lewey J, Shrank WH, Bowry AD, Kilabuk E, Brennan TA, Choudhry NK. Gender and racial disparities in adherence to statintherapy: A meta-analysis. Am Heart J. 2013;165(5):665-678, 678.e1. doi: 10.1016/j.ahj.2013.02.011. [DOI:10.1016/j.ahj.2013.02.011]
7. Franks P, Tancredi D, Winters P, Fiscella K. Cholesterol treatment with statins: who is left out and who makes it to goal? BMC Health Services Research. 2010;10:68. doi: 10.1186/1472-6963-10-68. [DOI:10.1186/1472-6963-10-68]
8. González-Chica DA, Mnisi Z, Avery J, Duszynski K, Doust J, Tideman P, et al. Effect of health literacy on quality of life amongst patients with ischaemic heart disease in Australian general practice. PLoS One. 2016;11(3):e0151079. doi: 10.1371/journal.pone.0151079. [DOI:10.1371/journal.pone.0151079]
9. Stocks NP, Ryan P, McElroy H, Allan J. Statin prescribing in Australia: socioeconomic and sex differences. Med J Aust. 2004;180(5):229-231. doi: 10.5694/j.1326-5377.2004.tb05891.x.
10. World Health Organization. The world health report 2000: health systems: improving performance. Geneva, Switzerland: World Health Organization; 2000.
11. Sridhar D, McKee M, Ooms G, Beiersmann C, Friedman E, Gouda H, et al. Universal health coverage and the right to health: from legal principle to post-2015 indicators. Int J Health Serv. 2015;45(3):495-506. doi:1177/0020731415584554.
12. Homaie Rad E, Kavosi Z, Arefnezhad M. Economic inequalities in dental care utilizations in Iran: Evidence from an urban region. Med J Islam Repub Iran. 2016;30:383.
13. Homaie Rad E, Khodaparast M. Inequity in health care financing in iran: progressive or regressive mechanism? Eurasian J Med. 2016;48(2):112-118. doi: 10.5152/eurasianjmed.2015.32. [DOI:10.5152/eurasianjmed.2015.32]
14. Shimony A, Grandi SM, Pilote L, Joseph L, O'Loughlin J, Paradis G, et al. Utilization of evidence-based therapy for acute coronary syndrome in high-income and low/middle-income countries. Am J Cardiol. 2014;113(5):793-797. doi: 10.1016/j.amjcard.2013.11.024. [DOI:10.1016/j.amjcard.2013.11.024]
15. Wallach-Kildemoes H, Andersen M, Diderichsen F, Lange T. Adherence to preventive statin therapy according to socioeconomic position. Eur J Clin Pharmacol. 2013;69(8):1553-1563. doi: 10.1007/s00228-013-1488-6. [DOI:10.1007/s00228-013-1488-6]
16. Chan DC, Shrank WH, Cutler D, Jan S, Fischer MA, Liu J, et al. Patient, physician, and payment predictors of statin adherence. Med Care. 2010;48(3):196-202. doi: 10.1097/MLR.0b013e3181c132ad. [DOI:10.1097/MLR.0b013e3181c132ad]
17. Ward PR, Noyce PR, St Leger AS. How equitable are GP practice prescribing rates for statins?: an ecological study in four primary care trusts in North West England. Int J Equity Health. 2007;6:2. doi: 10.1186/1475-9276-6-2. [DOI:10.1186/1475-9276-6-2]
18. Thomsen RW, Johnsen SP, Olesen AV, Mortensen JT, Bøggild H, Olsen J, et al. Socioeconomic gradient in use of statins among Danish patients: population-based cross-sectional study. Br J Clin Pharmacol. 2005;60(5):534-542. doi: 10.1111/j.1365-2125.2005.02494.x [DOI:10.1111/j.1365-2125.2005.02494.x]
19. Manderbacka K, Keskimäki I, Reunanen A, Klaukka T. Equity in the use of antithrombotic drugs, beta-blockers and statins among Finnish coronary patients. Int J Equity Health. 2008;7:16. doi: 10.1186/1475-9276-7-16. [DOI:10.1186/1475-9276-7-16]
20. McGuire A, Henderson J, Mooney GH. The economics of health care: an introductory text. Abingdon, UK: Routledge & Kegan Paul; 1988.
21. Jung K, Feldman R, McBean AM. Nonlinear pricing in drug benefits and medication use: the case of statin compliance in Medicare Part D. Health Serv Res. 2014;49(3):910-928. doi: 10.1111/1475-6773.12145. [DOI:10.1111/1475-6773.12145]
22. Karaca-Mandic P, Swenson T, Abraham JM, Kane RL. Association of Medicare Part D medication out-of-pocket costs with utilization of statin medications. Health Serv Res. 2013;48(4):1311-1333. doi: 10.1111/1475-6773.12022. [DOI:10.1111/1475-6773.12022]
23. Choudhry NK, Dugani S, Shrank WH, Polinski JM, Stark CE, Gupta R, et al. Despite increased use and sales of statins in India, per capita prescription rates remain far below high-income countries. Health Aff (Millwood). 2014;33(2):273-782. doi: 10.1377/hlthaff.2013.0388. [DOI:10.1377/hlthaff.2013.0388]
Send email to the article author
| Rights and permissions | |
 | This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Articles Copyright © The Author(s).
Owned by Guilan University of Medical Sciences.
Contact Information
cjhr Office, Guilan University of Medical Sciences
P.O.Box 93345-41938, Rasht, Iran
Journal Tel: +9813 33335820
Publisher Tel: +9821 453 55 000
Email: cjhr.gums@gmail.com
